IDEAYA Biosciences, Inc. IDYA
Sales up 3024.4%, free cash flow up to -$73.5M
XBRL, from each 10-KThe latest figures
Price and key numbers
All key numbers (34, from the latest 10-K and 10-Q)
- EPS (ttm)
- -4.50
- Sales (ttm)
- 36.5M
- Net income (ttm)
- -420.0M
- Sales growth
- n/m
- EPS growth
- -
- Sales Q/Q
- -95.1%
- Free cash flow
- -349.8M
- Gross margin
- -
- Oper. margin
- n/m
- Net margin
- n/m
- FCF margin
- -957.4%
- ROE
- -38.5%
- ROA
- -34.5%
- R&D / sales
- 143.9%
- Dividend
- -
- Debt/Eq
- -
- Curr. ratio
- 9.04
- Cash
- 261.5M
- Op. cash flow (ttm)
- -347.4M
- EBITDA
- -156.6M
- EBITDA margin
- -71.6%
- Quick ratio
- 9.04
- FCF after stock pay
- -119.6M
- Oper. margin low 5y
- -4671.1%
- Stock pay / sales
- 21.1%
- Shares out.
- 96.7M
- Shares Y/Y
- +8.3%
- Book / share
- 11.29
- Cash / share
- 2.70
- Sales / share
- 0.38
- Asset turnover
- 0.03
- Days sales out.
- 0
- Sales 3Y CAGR
- +62.5%
- Sales 5Y CAGR
- +62.1%
Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.
Revenue and net income, FY2019 to FY2025
Each fiscal year from its own 10-K · XBRL
From XBRL in each 10-K. Hover a bar for the line item and filing.
What the balance sheet holds, per share
Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used
- + Shareholders' equity $1.0B
- = Tangible book value $1.0B
Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.
IDYA against Health care peers
Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.
| Company | Revenue (ttm) | Sales growthFY | Gross marginttm | Net marginttm | ROEttm | FCF marginttm | Debt / equitylatest |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences, Inc. | $36.5M | - | - | - | -38.5% | -957.4% | - |
| RXRX Recursion Pharmaceuticals, Inc. | $68.2M | +26.9% | 5.0% | -697.1% | -52.5% | -458.0% | 0.01 |
| OCUL Ocular Therapeutix, Inc | $50.4M | -18.5% | 87.3% | -648.6% | -74.1% | -530.0% | 0.17 |
| ROIV Roivant Sciences Ltd. | $41.1M | -71.6% | - | -838.2% | -8.6% | -81.2% | - |
| CRSP CRISPR Therapeutics AG | $25.2M | -90.6% | - | - | -27.7% | - | 0.36 |
| CGON CG Oncology, Inc. | $6.2M | +255% | - | - | -24.0% | - | 0.00 |
Where the return on equity comes from
DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances
The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.
Profitability
-
Net margin below the peer median-1149.6% vs 6.8%
-
Return on equity below 15%-38.5%
-
A profit in 0 of 7 years
Cash and shareholders
-
Free cash flow positive in 1 of 7 years−$73.5M last year
-
Share count up over 5 years+257.9%
Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.
Contracted revenue and deferred revenue
Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL
Remaining performance obligations
Signed, not yet recognized $139.8M revenue under contracts the company has not delivered yet, Sep 30, 2026 · -2.3% on a year earlierBoth are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.
Income statement, balance sheet and cash flow
Statements · XBRL, each 10-K and 10-Q
IDYA's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 9. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.
Income statement
From EDGAR| FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 19.5M | 27.9M | 50.9M | 23.4M | 7.0M | 218.7M |
| R&D | 12.4M | 31.7M | 34.3M | 39.7M | 58.2M | 89.5M | 129.5M | 294.7M | 314.7M |
| SG&A | 2.1M | 4.7M | 10.0M | 15.2M | 20.1M | 23.9M | 28.3M | 39.3M | 63.3M |
| Operating income | -14.4M | -36.4M | -44.3M | -35.3M | -50.3M | -62.5M | -134.4M | -327.0M | -159.3M |
| Interest expense | 19K | 99K | 91K | 82K | 71K | 60K | 69K | 25K | 0 |
| Income tax | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -11.9M | -34.3M | -42.0M | -34.5M | -49.8M | -58.7M | -113.0M | -274.5M | -113.7M |
| EPS (diluted) | -17.06 | -35.92 | -3.36 | -1.40 | -1.41 | -1.42 | -1.96 | -3.36 | -1.28 |
| Diluted shares | - | - | - | 24.7M | 35.3M | 41.4M | 57.5M | 81.7M | 88.5M |
| Depreciation & amortization | 391K | 886K | 1.2M | 1.4M | 1.7M | 2.1M | 2.5M | 2.4M | 2.7M |
| EBITDA | -14.0M | -35.5M | -43.0M | -34.0M | -48.5M | -60.4M | -132.0M | -324.6M | -156.6M |
| Operating margin | - | - | - | -180.9% | -179.9% | -122.7% | -574.9% | -4671.1% | -72.8% |
| Net margin | - | - | - | -176.6% | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
| Revenue growth | - | - | - | - | +43.0% | +82.3% | -54.1% | -70.1% | +3024% |
Balance sheet
From EDGAR| FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash | 6.0M | 20.5M | 34.1M | 72.0M | 92.0M | 68.6M | 157.0M | 84.4M | 112.8M |
| Short-term investments | - | 69.5M | 64.9M | 211.5M | 154.7M | 296.2M | 368.1M | 591.9M | 526.6M |
| Receivables | - | - | - | 1.9M | 1.1M | 211K | 18K | 3K | - |
| Current assets | - | 90.7M | 101.7M | 288.6M | 251.0M | 370.5M | 532.6M | 689.7M | 666.7M |
| Property & equipment | - | 5.2M | 4.6M | 4.3M | 4.8M | 6.5M | 6.2M | 9.0M | 8.2M |
| Total assets | - | 96.5M | 113.0M | 298.3M | 381.3M | 388.0M | 649.3M | 1.1B | 1.1B |
| Accounts payable | - | 1.4M | 709K | 953K | 2.1M | 4.3M | 6.6M | 15.4M | 17.6M |
| Current liabilities | - | 5.4M | 6.9M | 38.6M | 45.2M | 31.7M | 27.1M | 46.1M | 58.8M |
| Total liabilities | - | 7.1M | 12.6M | 100.0M | 79.8M | 38.5M | 28.2M | 64.9M | 86.4M |
| Shareholders' equity | -15.7M | -48.9M | 100.4M | 198.3M | 301.5M | 349.5M | 621.1M | 1.1B | 1.0B |
| Retained earnings | - | -50.5M | -92.5M | -127.0M | -176.7M | -235.4M | -348.4M | -622.8M | -736.5M |
Cash flow
From EDGAR| FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -12.2M | -27.6M | -39.3M | 55.5M | -55.8M | -87.2M | -115.2M | -247.6M | -71.1M |
| Capital spending | 1.8M | 1.7M | 1.4M | 493K | 2.6M | 3.4M | 2.4M | 3.9M | 2.4M |
| Free cash flow | -14.0M | -29.3M | -40.7M | 55.0M | -58.4M | -90.6M | -117.6M | -251.4M | -73.5M |
| Stock-based pay (added back) | 136K | 950K | 2.2M | 3.6M | 8.2M | 11.6M | 18.5M | 34.7M | 46.1M |
| Free cash flow after stock pay | -14.1M | -30.3M | -42.8M | 51.4M | -66.7M | -102.2M | -136.1M | -286.2M | -119.6M |
| Investing cash flow | -8.9M | -63.2M | 2.3M | -146.2M | -69.7M | -33.4M | -158.5M | -502.6M | 70.0M |
| Financing cash flow | 17.5M | 105.4M | 50.6M | 128.8M | 145.5M | 97.2M | 362.7M | 677.6M | 29.8M |
Stock-based pay and leases
From EDGAR| FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Stock-based pay (expense) | 136K | 950K | 2.2M | 3.6M | 8.2M | 11.6M | 18.5M | 34.7M | 46.1M |
| Stock-based pay / revenue | - | - | - | 18.5% | 29.5% | 22.8% | 79.1% | 496.4% | 21.1% |
| Operating lease cost | - | - | - | - | 1.7M | 1.7M | 1.7M | 1.9M | 5.0M |
| Operating lease cash paid | - | - | 1.7M | 1.7M | 1.9M | 2.0M | 2.0M | 1.7M | 400K |
| Right-of-use assets | - | 6.1M | 5.1M | 5.2M | 3.9M | 2.5M | 2.2M | 18.8M | 22.9M |
| Operating lease liabilities | - | 8.0M | 6.8M | 6.7M | 5.2M | 3.5M | 2.9M | 19.2M | 27.9M |
From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.
Sources
Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.
Also
Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IDYA/export.csv") into a cell.